05.10.21|James SpiroProceeds from the investment are expected to provide Silenseed with liquidity to fund the company’s Phase III clinical trial
25.02.20|CTechThe company intends to use the funding to advance its immuno-oncology drug candidates, especially its lead product, DSP107, tested for the treatment of solid tumors
28.03.18|Lilach BaumerAs part of the deal, InSight commits to help develop CureTech’s lead product, which is currently in advanced clinical trials